<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE331nnn/GSE331507/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><gds_type> Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE331507</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Multi-omics profiling of glioma cells treated with I-BRD9</name><description>BRD9 is a glioma-associated epigenetic regulator. This study profiles transcriptomic and chromatin-level changes in glioma cells after I-BRD9 treatment. RNA-seq was performed in U87MG and SKMG-1 cells, and ATAC-seq and BRD9 CUT&amp;Tag were performed in U87MG cells. These datasets were used to characterize changes in gene expression, chromatin accessibility, and BRD9-associated chromatin signals after BRD9 inhibition.</description><dates><publication>2026/05/25</publication></dates><accession>GSE331507</accession><cross_references><GSM>GSM9748305</GSM><GSM>GSM9748304</GSM><GSM>GSM9748307</GSM><GSM>GSM9748306</GSM><GSM>GSM9748301</GSM><GSM>GSM9748289</GSM><GSM>GSM9748300</GSM><GSM>GSM9748303</GSM><GSM>GSM9748302</GSM><GSM>GSM9748297</GSM><GSM>GSM9748296</GSM><GSM>GSM9748288</GSM><GSM>GSM9748299</GSM><GSM>GSM9748298</GSM><GSM>GSM9748293</GSM><GSM>GSM9748292</GSM><GSM>GSM9748295</GSM><GSM>GSM9748294</GSM><GSM>GSM9748291</GSM><GSM>GSM9748290</GSM><GPL>34284</GPL><GSE>331507</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>